{"brief_title": "GL701 (Prestara\u2122) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids", "brief_summary": "Open label safety and efficacy follow-up.", "detailed_description": "This was a randomized, multi-center, open-label, parallel-group, trial of prasterone 200 or 100 mg/day for 12 months in women with lupus receiving glucocorticoid therapy who had completed an earlier 6-month randomized, placebo-controlled study (NCT00053560. Bone Mineral Density assessments were performed at baseline and at months 6 and 12.", "condition": "Systemic Lupus Erythematosus", "intervention_type": "Drug", "intervention_name": "Prasterone (GL701)", "description": "There were 4 arms to the study:\nDuring a previous 6 month db RCT, patients received either prasterone 200 mg/day or placebo. Upon entry into this open-label study, they were re-assigned by randomized allocation to receive either prasterone 200 mg/day or 100 mg/day. Hence, there were 4 possible treatment arms extending over the 18 months of observation between the double-blind study and the subsequent 12 month open-label extension study.", "criteria": "Inclusion Criteria: - Patient has completed the full 6 month treatment period with study drug in the previous Genelabs' clinical study GL02-01. - Concomitant treatment with prednisone (or equivalent) at a dose of \u2265 5mg/day. - Patient has read and signed an Informed Consent Form. If the patient is not fluent in English, the Informed Consent must be signed in her native language. Exclusion Criteria: - Patient has had a serious study drug related adverse reaction at any time during the previous GL02-01 study. - Any condition which in the Investigator's or Sponsor's opinion is sufficient to prevent adequate compliance with the study or likely to confuse follow-up evaluation (e.g., alcoholism, drug addiction, acute withdrawal from chemical dependency, psychiatric disease). MEDICATIONS PROHIBITED AT ANY TIME DURING THE STUDY - Calcitonin - Bisphosphonates - Fluoride at pharmacologic dose - Strontium at pharmacologic dose - Estrogenic steroids (except oral contraceptives) - Selective Estrogen Receptor Modulator (raloxifene) - Parathyroid hormone - Any androgens, including prescription or nutritional supplement DHEA, other than study drug - Additional Calcium supplements other than those prescribed as part of this study", "gender": "Female", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00082511.xml"}